Effects of Structural Integration on Chest Wall Expansion Among COPD Patients

August 18, 2026 updated by: Mohtishim Ahmed, Green International University

Effects of "The 10-Series of Structural Integration" on Chest Wall Expansion Among COPD Patients

The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Participants receiving Structural Integration in addition to conventional pulmonary rehabilitation will be compared with those receiving conventional pulmonary rehabilitation alone. Chest wall expansion will serve as the primary outcome, while pulmonary function, dyspnea, functional exercise capacity, and quality of life may be evaluated as secondary outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinically diagnosed stable COPD according to GOLD criteria
  • GOLD stage II or III
  • No acute exacerbation within the previous four weeks
  • Able to ambulate independently
  • Medically cleared to participate in pulmonary rehabilitation
  • Willing to provide written informed consent

Exclusion Criteria:

  • Severe cardiovascular disease contraindicating exercise
  • Recent thoracic or abdominal surgery (<6 months)
  • Rib fractures or severe chest wall deformity
  • Neurological disorders affecting mobility
  • Active malignancy
  • Severe osteoporosis with high fracture risk
  • Previous Structural Integration treatment within the last year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental Group
Other: Structural Integration with Conventional Pulmonary Rehabilitation
  • Conventional pulmonary rehabilitation.
  • The complete 10-Series of Structural Integration, delivered by a certified Structural Integration practitioner/physiotherapist.
Active Comparator: Control Group
Other: Pulmonary Rehabilitation only
Participants receive only the conventional pulmonary rehabilitation program.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chest Wall Expansion
Time Frame: Before the start and end of 10 weeks

Chest wall expansion will be measured using a flexible measuring tape at:

  • Axillary level
  • Xiphoid level
  • Lower thoracic level (10th rib) Measurements will be taken during maximal inspiration and maximal expiration. The difference (in centimeters) will be recorded. Three readings will be obtained at each level, and the average value will be used for analysis.
Before the start and end of 10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Green International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

November 15, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

August 4, 2026

First Submitted That Met QC Criteria

August 4, 2026

First Posted (Actual)

August 7, 2026

Study Record Updates

Last Update Posted (Actual)

August 19, 2026

Last Update Submitted That Met QC Criteria

August 18, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GIU/IRB/110047-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The details will be provided to researchers subject to reason of IPD requirement. The record will be provided through Email. Only official Emails will be entertained.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe